- Home
- ICCC vs SER Comparison
ICCC vs SER Comparison
Compare ICCC & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCC
- SER
- Stock Information
- Founded
- ICCC 1982
- SER 2017
- Country
- ICCC United States
- SER United States
- Employees
- ICCC N/A
- SER N/A
- Industry
- ICCC Biotechnology: Pharmaceutical Preparations
- SER Biotechnology: Pharmaceutical Preparations
- Sector
- ICCC Health Care
- SER Health Care
- Exchange
- ICCC Nasdaq
- SER Nasdaq
- Market Cap
- ICCC 55.5M
- SER 55.2M
- IPO Year
- ICCC 1987
- SER 2018
- Fundamental
- Price
- ICCC $6.19
- SER $3.96
- Analyst Decision
- ICCC
- SER Strong Buy
- Analyst Count
- ICCC 0
- SER 2
- Target Price
- ICCC N/A
- SER $13.00
- AVG Volume (30 Days)
- ICCC 18.9K
- SER 28.8K
- Earning Date
- ICCC 11-13-2025
- SER 11-11-2025
- Dividend Yield
- ICCC N/A
- SER N/A
- EPS Growth
- ICCC N/A
- SER N/A
- EPS
- ICCC 0.20
- SER N/A
- Revenue
- ICCC $28,274,756.00
- SER $130,000.00
- Revenue This Year
- ICCC N/A
- SER $134.46
- Revenue Next Year
- ICCC N/A
- SER N/A
- P/E Ratio
- ICCC $31.45
- SER N/A
- Revenue Growth
- ICCC 21.75
- SER N/A
- 52 Week Low
- ICCC $3.38
- SER $3.70
- 52 Week High
- ICCC $7.60
- SER $7.92
- Technical
- Relative Strength Index (RSI)
- ICCC 50.47
- SER 29.95
- Support Level
- ICCC $6.07
- SER $4.60
- Resistance Level
- ICCC $6.31
- SER $5.00
- Average True Range (ATR)
- ICCC 0.28
- SER 0.29
- MACD
- ICCC 0.01
- SER -0.11
- Stochastic Oscillator
- ICCC 44.19
- SER 16.40
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.